Entera Bio Ltd. — Company profile
Healthcare · Biotechnology · Israel
Last price 3.2 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 556.55M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Details
| Name | Entera Bio Ltd. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 22 |
| Founded | 2010 |
| Ipo Date | 2018-06-28 |
| Ceo | Miranda Toledano |
| Country | Israel |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | IL0011429839 |
| Cusip | M40527109 |
| Cik | 0001638097 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Miranda J. Toledano M.B.A. | Chief Executive Officer and Director |
| Dr. Hillel Galitzer M.B.A., Ph.D. | Chief Operating Officer |
| Dr. Rachel B. Wagman | Chief Clinical Advisor |
| Cherin Smith | Executive Vice President and Head of Clinical Operations |
| Dr. Constantin Itin Ph.D., R.Ph. | Head of Biopharmaceutics and Bioanalytics |
| Michele McDermott | MD and Executive Vice President of Medical Affairs |
| Riccardo Paolo Camisasca M.D. | Chief Medical Officer |
Contact
| Address | Kiryat Hadassah Minrav Building, 5th Floor, Jerusalem, 9112002, Israel |
| Phone | 972 2 532 7151 |
| Website | https://enterabio.com |